Abstract
The thalidomide episode was primarily responsible for strengthening or initiating leglislation and codes of practice, in many countries, on drug safety evaluation, and the environmental impact of these measures is discussed. The availability and distribution of pharmaceutical products constitute a separate issue, and are treated by reference to abuse, misuse, overdosage and the utilisation of available hospital beds.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.